Sort by
Refine Your Search
-
Clinician Researcher/Group Leader in Cancer Cell Therapies About QIMR Berghofer: QIMR Berghofer is a world-leading translational medical research institute focused on improving health by developing
-
compounds, cancer or immunotherapy research. The candidate should be familiar with air-sensitive chemistry and general analytical techniques such as FTIR, NMR, electrochemistry, etc. Desirable criteria
-
Status: Closed Applications open: 7/07/2023 Applications close: 25/08/2023 View printable version [.pdf] About this scholarship Description/Applicant information Lung cancer is the leading cause
-
Scholarship will fund a 3-year PhD candidature to work in the Cancer, Ageing & Vaccine Laboratory (SHBS). Project is a collaboration with WEHI and Hudson Institute to improve cancer diagnosis
-
referees. The immune system plays a pivotal role in cancer prevention, development and therapy. We are currently interested in two natural compounds that have the potential to modulate immune responses and
-
contact details of two referees. Co-supervised by Dr April Kartikasari, Dr Andrew Stephens (Hudson Research Institute) and Professor Clare Scott (WEHI). Epithelial ovarian cancer is one of the leading
-
A funded PhD position is supported through Medical Research Future Fund grant MRFCRI000188, "Enhanced INfection Surveillance Transforming Excellence In National cancer care (EINSTEIN)". The project
-
Using cancer and vaccine clinical trials, the project will use RNAseq, epigenetics and flowcytometry, as well as classic immunological techniques. Using cancer and vaccine clinical trials
-
-compounds as anti-ovarian cancer therapeutics. Scholarship will fund a 3 year PhD candidature to work in the Chemistry Department of the RMIT School of Science CAMIC Laboratory. Project is a collaboration
-
the treatment landscape for metastatic melanoma, an aggressive form of skin cancer. Although new therapies work for some patients, there are many that do not respond or become resistant to treatment. In